Alk­er­mes' $194M pay­ment from Janssen gets ap­proval from court

Last year
Pharma
Law

Slynd birth con­trol drug­mak­er Ex­eltis hit with FDA let­ter over mis­lead­ing so­cial me­dia pro­mo­tion

Last year
FDA+
Marketing

FDA sets Oc­to­ber ad­comm to dis­cuss full ap­proval for Am­gen’s Lumakras to treat sec­ond-line lung can­cer

Last year
Pharma
FDA+

FDA OKs In­grez­za for treat­ing chorea as­so­ci­at­ed with Hunt­ing­ton’s; Abi­vax inks agree­ment for up to $163M in debt ...

Last year
News Briefing

Leo Phar­ma spend­ing $14M up­front to ac­quire Tim­ber

Last year
Deals
R&D

Ex-em­ploy­ees of Ra­maswamy's in­vest­ment com­pa­ny sue, claim­ing they were mis­led or pushed to vi­o­late se­cu­ri­ties law

Last year
People
Law

FDA puts par­tial hold on Gilead’s CD47 hope­ful in AML

Last year
R&D
FDA+

Skye ac­quires Bird Rock Bio, weeks af­ter No­vo Nordisk says it will buy a CB1 de­vel­op­er

Last year
Financing
Startups

The End­points Slack In­ter­view: NewLim­it's Ja­cob Kim­mel brings an­ti-ag­ing back to re­al­i­ty

Last year
People

An­dreessen Horowitz-backed start­up lands $200M for AI-based drug dis­cov­ery

Last year
Financing
R&D

Af­ter Prometheus sale, Mark McKen­na heads to an­oth­er au­toim­mune biotech as chair of Apogee

Last year
People

Mod­er­na and CARs­gen team up on CAR-T cell ther­a­py and mR­NA can­cer vac­cine com­bo

Last year
Deals

Af­ter two flops, Roche and Ex­elix­is post ear­ly PhI­II win for Tecen­triq/Cabome­tyx com­bo — but will wait for OS da­ta

Last year
R&D
Pharma

Re­gen­eron an­ti­body se­cures FDA win; Yan­copou­los in ex­pan­sive Q&A; Bio­gen’s Rea­ta bid­ding war de­tails re­vealed; ...

Last year
Weekly

FDA ap­proves high dose of Re­gen­eron's eye treat­ment Eylea in quick bounce­back from June re­jec­tion

Last year
Pharma
FDA+

Ab­b­Vie ex­plores the emo­tion­al side of rare chron­ic can­cer in on­go­ing CLL video se­ries

Last year
Pharma
Marketing

FDA ap­proves Re­gen­eron's an­ti­body for rare im­mune dis­ease, re­solves man­u­fac­tur­ing is­sues for afliber­cept

Last year
Pharma
FDA+

AARP, in am­i­cus brief, ar­gues that CMS ne­go­ti­at­ing drug prices is in the pub­lic in­ter­est

Last year
Pharma
FDA+

Mul­ti-task­ing doc­tors at home are watch­ing TV and re­search­ing phar­ma ads — on Google and even EMRs, sur­vey finds

Last year
Pharma
Marketing

Mer­ck­'s Welireg meets co-pri­ma­ry end­point in kid­ney can­cer PhI­II; Noveome rais­es half of planned $40M VC round

Last year
News Briefing

Mod­er­na's up­dat­ed Covid vac­cine like­ly pro­vides pro­tec­tion against new vari­ants, but up­take re­mains un­cer­tain

Last year
R&D

ARCH's lat­est biotech, tar­get­ing can­cer re­cur­rence, emerges from Co­lum­bia pro­fes­sor who worked on Biden's moon­shot

Last year
Financing
Startups

Flag­ship re­cruits ex-Ma­gen­ta CEO to lead Am­per­sand; Bio­gen's head of re­search leaves for All­tr­na

Last year
Peer Review

Cis­platin, car­bo­platin short­ages raise ques­tions about im­pact on clin­i­cal tri­als 

Last year
R&D
First page Previous page 293294295296297298299 Next page Last page
A service from the Financial Times